Abemaciclib mesylate (LY2835219)

Catalog No.S7158

For research use only.

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS No. 1231930-82-7

Selleck's Abemaciclib mesylate (LY2835219) has been cited by 68 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Other CDK Products

Biological Activity

Description Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Targets
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
In vitro

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells MmjqSpVv[3Srb36gZZN{[Xl? MXiyOEBp NW[zXXBJUW6qaXLpeIlwdiCxZjDDSGs1NzZiaX6gbJVu[W5iQ1;MU|IxPSClZXzsd{Bie3Onc4Pl[EBieyCvYYjpcZVuKGOnbHygZ5lkdGViYYLy[ZN1KGG2IFexJJBp[XOnIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?= NH7PNVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
human COLO205 cells NGC5c4ZHfW6ldHnvckBie3OjeR?= MmPtNlQhcA>? Mmf0TY5pcWKrdHnvckBw\iCFRFu0M|YhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGLiJJBpd3OyaH;yfYxifGmxbjDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBt[XOncj3zZ4FvdmmwZzDmcJVwemW|Y3XuZ4UhdWmlcn;wcIF1\SCleYTvcYV1emmlIHHuZYx6e2m| NV[2R4d{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
insect cells  NV72N|dCTnWwY4Tpc44h[XO|YYm= NFy4PWU2OCCvaX7z M2C2UGlvcGmkaYTpc44hd2ZiaIXtZY4hS0SNND;jfYNtcW5iREGg[ZhxemW|c3XkJIlvKGmwc3XjeEBk\WyuczDhd5Nme3OnZDDhd{BxcG:|cHjvdplt[XSrb36gc4YhS1SURjDh[pRmeiB3MDDtbY5{KGK7IH3pZ5JweGyjdHWgd4NqdnSrbHzheIlwdiClb4XueIVzNCCLQ{WwQVIhdk1? MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUW1O|EoRjJ4MUG1OVcyRC:jPh?=
insect cells  MnvISpVv[3Srb36gZZN{[Xl? M{nOb|UxKG2rboO= NUXITFdxS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBpfW2jbjDDSGs1N2O7Y3zpckBFOSCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG:{eXzheIlwdiCxZjDDWHJHKGGodHXyJFUxKG2rboOgZpkhVWmlaHHlcIl{NU2nboTlckBxdG:2IHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKEGWUDygT4k:OC54IH7N NIPMcFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
HCT116 Mk\IRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYK3NkBpenN? MlXHTWM2OCB;IECuOVQh|ryP MlrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkWzOFEoRjNyMU[1N|QyRC:jPh?=
MCF7 NWLZfZNSSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NFz2NJI4OiCqcoO= M1fqV2lEPTBiPTCwMlcyKM7:TR?= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4NUO0NUc,OzBzNkWzOFE9N2F-
PANC1 M2r1T2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MkPNO|IhcHK| M3L1NGlEPTBiPTC1Mlk1KM7:TR?= NIrZRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1OSd-M{CxOlU{PDF:L3G+
Sf9 NEDnXVBHfW6ldHnvckBie3OjeR?= MljDTY5pcWKrdHnvckBw\iCFRFuxM2N6[2yrbjDCJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqemGuIHnu[oVkfGWmIHnud4VkfCCVZkmgZ4VtdHNidYPpcochcGm|dH;u[UBJOSCjczDzeYJ{fHKjdHWgbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iNTN|UG3BWHAtKEmFNUCgQUAxNjN5MTFOwG0v NXvVZopjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OFE5PTNpPkK2O|QyQDV|PD;hQi=>
Sf9 MXvGeY5kfGmxbjDhd5NigQ>? NYHhUJJiQTBibXnudy=> MlvkTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqNDD0c{A{ODNicnXzbYR2\XNrL3P5Z4xqdiCGMTCoOEB1dyB{OUWgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiC|ZkmgZ4VtdHNidYPpcochSy22ZYLtbY5idCC{ZYTpco9jdGG|dH;tZUBnemGpbXXueEBieyC|dXLzeJJifGViYX\0[ZIhQTBibXnud{BjgSCdZ3HtcYEuOzOSXVHUVEBj[XOnZDDtbYNzd2KndHGgd4NqdnSrbHzheIlwdiClb4XueIlvNCCNaTC9JFAvODB{IN88UU4> Mk\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN|YoRjJ5MUexNFM3RC:jPh?=
Sf9 Mne1SpVv[3Srb36gZZN{[Xl? MlzrPVAhdWmwcx?= NIfWcoRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKGi3bXHuJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCFRFu2JEgyKHSxIEOyOkBz\XOrZIXld{kw[3mlbHnuJGQyKCh2IITvJFI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDDMZRmem2rbnHsJJJmfGmwb3LsZZN1d22jIH\yZYdu\W62IHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHto[W2vYT2zN3BeSVSSIHLhd4VlKG2rY4LvZoV1[SC|Y3nueIltdGFuIFvpJF0hOC5yMTFOwG0v MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 MWLGeY5kfGmxbjDhd5NigQ>? M3jt[WlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXN4LYTh[4dm\CCFRFu3M4N6[2yrbjDIM24ufGW{bXnuZYwhT1OWLYTh[4dm\CCPQWSxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yClZHu3JJN2[nO2cnH0[UBx\XC2aXTlMEBMcSB;IEOuPVEh|ryPLh?= M1m2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
COLO205 M3LwTWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWX2OIlPQTZiaILz NXvIboFHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGGodHXyJFk3KGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDBwNE[g{txONg>? M2i2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEe0NlU1Lz5{OUC3OFI2PDxxYU6=
U87MG NUHSNZd1SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M3zzUFczKGi{cx?= NV7KfWNYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bi\nSncjC3NkBpenNiYomgSGFRUSC|dHHpcolv\yCkYYPl[EBie3OjeTygTWM2OCB;IECuNFQ5OSEQvF2u MkTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{NEe4OVcoRjJ7MkS3PFU4RC:jPh?=
Sf9 NGC0cVdHfW6ldHnvckBie3OjeR?= NWTrXGw4UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNNDCoV|QhfG9iRUOwN{Bz\XOrZIXld{kwS3mlbHnuJGQyKCiTNDD0c{BKOjl3IILld4llfWW|KTDlfJBz\XO|ZXSgbY4he2Z7IHPlcIx{KHW|aX7nJHJjKHC{b4TlbY4hMDd5MzD0c{A6OjhicnXzbYR2\XNrIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDbN|NRZS2DVGCgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkCwNkDPxE1w MkHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 NE\mT5JHfW6ldHnvckBie3OjeR?= NHK3[5k6OCCvaX7z MX7Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFPET|Yh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSCrboPlZ5Qh[2WubIOgeZNqdmdiaHnzeI9v\SCKMTDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDBSHAuT2yxIHHzd4F6NCCLQ{WwJF0hOC5yMEe4JO69VS5? MlThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 NGfNXYlHfW6ldHnvckBie3OjeR?= MYDJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs1KCiPMTD0c{BCOzJ4IILld4llfWW|KT;DfYNtcW5iREGgLHE1KHSxIFmyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiUnKgdJJwfGWrbjCoO|c{KHSxIEmyPEBz\XOrZIXld{kh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFt|M2DdMWFVWCCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODFizszNMi=> MoftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 MmXoSpVv[3Srb36gZZN{[Xl? MYC5NEBucW6| MlWxTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDSGsyN0O7Y3zpckBFOyCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDobZN1d26nIFixJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JGFFWC2JbH:gZZN{[XluIFnDOVAhRSByLkC1OkDPxE1w NX;2NXVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Nlk5OzJpPkK5OFI6QDN{PD;hQi=>
MDA-MB-231 NE\6TVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGw NWXoWnY1PzJiaILz NWfZSnNmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCGQWDJJJN1[WmwaX7nJIJie2WmIHHzd4F6NCCLQ{WwJF0hOC5zOUGg{txONg>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{OUizNkc,Ojl2Mkm4N|I9N2F-
COLO205 M4TqcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5? Mke1PVYhcHK| MnTtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gNE4zOTdizszNMi=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3OUK3OEc,Ojl2NUmyO|Q9N2F-
MDA-MB-468 NUK0U3RNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?= NHXZO3o6PiCqcoO= NIPwempCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12NkigZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB2LkiwPEDPxE1w MlfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=
COLO205 MlrETY5pcWKrdHnvckBw\iCFRFu0JIlvKGi3bXHu MYCwMlEhfG9iMUCgeW0> MUWyOEBpenN? MWfJcohq[mm2aX;uJI9nKEOGS{SgbY4hcHWvYX6gR29NVzJyNTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hfG:2YXygVoIheHKxdHXpckBt\X[nbDDheEAxNjFidH:gNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?= M1;OSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=
COLO205 M2[1dmNmdGxiY4njcIUh[XO|YYm= M132SJVxKHSxIEGwJJVO MYiyOEBpenN? NGDrWZlE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBEV0yRMkC1JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJJVxKHSxIEGwJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> M1PIdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=
Assay
Methods Test Index PMID
Western blot p-Rb(S780) / Rb / p21 ; p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR ; pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2 26909611 27748766
Growth inhibition assay Cell viability 26909611
In vivo LY2835219 saturates BBB efflux with an unbound plasma IC50 of about 95 nM. The percent of dose in brain for LY2835219-MsOH is 0.5–3.9%. In both a subcutaneous and intracranial human glioblastoma model (U87MG), LY2835219-MsOH suppressed tumor growth in a dose-dependent manner both as a single agent, and in combination with temozolomide. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.

100mg/mL

Chemical Information

Molecular Weight 602.7
Formula

C27H32F2N8.CH4O3S

CAS No. 1231930-82-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05440786 Not yet recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Sarcoma Ewing|Neoplasm Metastasis Eli Lilly and Company August 15 2022 Phase 2
NCT05386108 Not yet recruiting Drug: Abemaciclib|Drug: Elacestrant Breast Neoplasms|Brain Neoplasms|Neoplasms by Site|Neoplasms|Breast Diseases|Central Nervous System Neoplasms|Brain Diseases|Central Nervous System Diseases Stemline Therapeutics Inc. August 2022 Phase 1|Phase 2
NCT04791384 Recruiting Drug: Abemaciclib|Drug: Elacestrant Breast Cancer Criterium Inc. April 21 2022 Phase 1|Phase 2
NCT05169567 Recruiting Drug: Abemaciclib|Drug: Fulvestrant|Drug: Placebo Breast Neoplasm|Neoplasm Metastasis Eli Lilly and Company March 11 2022 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is your product S7158 LY2835219 “mesylate salt form”?

Answer:
Our S7158 LY2835219 is mesylate salt form.

Tags: buy Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219) supplier | purchase Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219) cost | Abemaciclib mesylate (LY2835219) manufacturer | order Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219) distributor